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Previewsemerging field of targeting epigenetic re-
gulators in cancer, the results presented
in these articles highlight the potential of
using such therapies, not only in AML,
but perhaps in other cancers that are
dependent on aberrant epigenetic activity
for survival.
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TLX1 and TLX3 are two closely-related homeobox transcriptional repressors frequently misexpressed and
translocated in T cell acute lymphoblastic leukemia (T-ALL). In this issue of Cancer Cell, Dadi et al. provide
new insights into how these factors are recruited by ETS-1 to the TCRa enhancer and actively repress differ-
entiation.In the majority of human cancers, tumor
cells tend to share aspects of their identity
with a corresponding cell of origin, a prop-
erty that has proved useful for diagnosis
in the clinic and provided researchers
with a wide range of potential therapeutic
targets. In particular, acute lymphoblastic
leukemia (ALL) often presents as a snap-
shot of lymphocyte differentiation, based
on surfacemarker expression and charac-
teristic molecular genetic signatures
(Aifantis et al., 2008). A large amount of
data over the last decade has underlined
the connection between physiological
lymphocyte differentiation and the trans-
formation events that lead to ALL.
Whole-genome profiling and sequencing
studies have suggested that some of the
most common mutational targets in ALL
are also key regulators of normal differen-
tiation, including IKZF1andPAX5 inB-ALL
and NOTCH1 and GATA3 in T cell ALL(T-ALL) (Mullighan and Downing, 2009).
Such findings have suggested that certain
oncogenic lesions have the ability to
‘‘freeze’’ cellular differentiation at distinct
stages. Therefore, a thorough under-
standing of how oncogenes halt develop-
mental processes will provide clues
toward the reinforcement of differentiation
and, presumably, the desired outcomesof
cell cycle exit and/or programmed cell
death. In this issue of Cancer Cell, Dadi
et al. (2012) reveal how two such onco-
genes (TLX1 and TLX3) manage to inter-
fere with a critical stage of T cell differenti-
ation, leading to development of a subset
of T-ALL.
T cell differentiation and ALL are
ideal models to study such oncogenic
effects due to our detailed knowledge on
the phenotypic and molecular programs
of differentiation. T cells mature in the
thymus following a highly orchestratedprocess, controlled by cell intrinsic (tran-
scription factors) and cell extrinsic
(antigen, cytokines, and chemokines)
factors. Uncommitted, multipotent pro-
genitors enter the thymus through the
cortico-medullary junction, sense Notch
ligands, and initiate commitment to the
T cell lineage. At this point the T cell
receptor (TCR) b, g, and d loci become
accessible and the outcome of rearrange-
ment leads to either the differentiation
toward the gd lineage or (as it happens
with the vast majority of T cells) the
expression of the pre-TCR, which helps
drive cellular proliferation and leads to
the CD4+8+ stage. At this stage, the
TCRa locus undergoes recombination
which leads to the surface expression
of a TCRab and subsequent selection
events (Sleckman et al., 1998). RAG-
mediated rearrangement of the TCRa
locus is a process controlled by distinctl 21, April 17, 2012 ª2012 Elsevier Inc. 453
Figure 1. TLX-Mediated Repression of the TCRa Enhancer
Under normal conditions of ab T cell development (top), transcriptional access to the TCRa locus at the late double-negative (DN) to CD4+8+ stage is imparted
primarily by the function of the Ea enhancer, shown bound by its transcriptional activators ETS-1, RUNX1, and LEF1. The onset of Va-Ja recombination begins
with transcription from the TEA promoter and increased histone acetylation throughout the Ja region. In a subset of T cell leukemias where TLX1 or TLX3 are
misexpressed (bottom), Dadi et al. (2012) found that ETS-1 can recruit TLX1/3 to Ea and that this correlateswith an enrichment of repressive histonemodifications
and lack of TCRA gene expression, ultimately leading to an arrest in differentiation.
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Previewscis-regulatory regions, most notably the
Ea enhancer, and a large number of
factors regulating chromatin accessibility,
locus contraction and gene transcription
(Schatz and Swanson, 2011). Interest-
ingly, topology is essential for normal
maturation, suggesting an intimate rela-
tionship between developing progenitors
and thymic microenvironments. Human
and mouse T cell differentiation follow
similar rules with very small differences,
underlining the evolutionary conservation
of such a critical process. Human T-ALL
cases can be roughly separated into three
categories, reminiscent of physiological
developmental stages: (1) immature, early
T-ALL, expressing markers and genes
characteristic for pre-committed progeni-
tors; (2) early cortical, ab-committed
thymocytes, harboring TCRb rearrange-
ments and (in most cases) expressing
a pre-TCR; and (3) late, TCR-expressing
leukemia, with full rearrangement of the
TCRa locus.
In concordance with previous studies,
Dadi et al. (2012) found that TLX1 and
TLX3 are overexpressed in a significant
fraction of T-ALL, and their expression
defines a molecular signature character-
istic of early cortical thymocytes. TLX1 is
overexpressed in 5%–10% of pediatric454 Cancer Cell 21, April 17, 2012 ª2012 Elsand up to 30% of adult T-ALL as a conse-
quence of chromosomal translocations.
Similarly, TLX3 is overexpressed as a
result of t(5;14)(q35;q32) in approximately
25% of pediatric and 5%–10% of adult
T-ALL cases. TLX1, which is not ex-
pressed during physiological T cell differ-
entiation, was first implicated in T-ALL
from a t(10;14) translocation by Hatano
et al. (1991). As a result of this transloca-
tion, TLX1 is ectopically expressed in
thymocytes driven by cis-regulatory ele-
ments of the TCRa/d locus. The targeting
of antigen receptor loci by translocations
is a frequent event in ALL, most likely
caused by the function of RAG nucleases
and the accessible state of the chromatin
during specific differentiation stages.
TLX1/3 overexpression defines a distinct
subgroup of T-ALL, one that predicts an
overall favorable prognosis, bears char-
acteristic molecular and cellular pheno-
types, and is enriched in NUP12-ABL1
fusions or mutations in WT1, PHF6, and
RUNX1 (Van Vlierberghe et al., 2010).
Transgenic expression of TLX1 in the
thymus of mice eventually leads to T cell
neoplasms (De Keersmaecker et al.,
2010). Interestingly, these TLX1+ tumors
are prone to aneuploidy and showmarked
defects in the activation of normal mitoticevier Inc.checkpoints, possibly due to deregulated
expression of Chek1. Further analysis re-
vealed that ectopic TLX1 expression
alone is likely insufficient to induce T cell
leukemia but leads to aberrant T cell
differentiation and sets the stage for
secondary transformation events. Indeed,
genetic lesions in loci encoding known
regulators of lymphocytic transformation
were identified, including mutations in
Notch1, Pten, Tp53 and, most notably,
Bcl11B, a factor controlling early T cell
progenitor differentiation in the thymus
(Gutierrez et al., 2011). Altogether, these
data suggested that TLX1 might act first
and foremost as an antagonist of physio-
logical T cell development. However, the
mechanism by which TLX1/3 could exert
this effect remained elusive.
Intriguingly, Dadi et al. (2012) found
that TLX1/3+ leukemias were significantly
less likely to have TCRa rearrange-
ments. Accordingly, increased levels of
the repressive histone mark H3K27me3
was observed across the TCRa locus in
these leukemias, suggesting that the un-
rearranged TCRa segments were epige-
netically silenced in the presence of
TLX1/3. However, their most critical find-
ing is that the TLX factors could directly
interfere with Ea function through
Cancer Cell
Previewsinteraction with ETS1, a critical compo-
nent of the complex that binds and acti-
vates Ea (Figure 1). To test the biological
significance of this interaction on the
enhancer element, the authors silenced
TLX1/3 in human T-ALL cell lines and
observed increases in differentiation and
cell death, suggesting abortive differenti-
ation and induction of apoptosis. Ectopic
expression of rearranged TCRa caused
identical effects. These findings therefore
connect proper TCR rearrangement and
expression to tumor differentiation state.
Altogether, the work of Dadi et al. (2012)
presents a novel mechanism of differenti-
ation arrest orchestrated by the TLX
oncogenes in the induction and mainte-
nance of T-ALL. To this end, it will be
important to determinewhether additional
transcriptional targets that are potentially
perturbed by TLX1/3 are also important
for progression of the disease. This is an
important question as the differentiation
defects seen in TLX1 transgenic mice
are distinct from those caused by
paucity of TCRa rearrangement in human
leukemia. One such example could be the
downregulation BCL11B, a target of TLX1that is essential for T cell commitment.
Further investigation on the potential
synergistic role other factors play in the
TCR recombination (Polycomb complex,
the CTCF insulator protein, and others)
and on the mechanisms leading to sus-
tained expression of the TLX proteins
will shed light on the intricacies of this
leukemia. Ultimately, the most intriguing
implication of this study is whether there
are means of regulating TLX function
using targeted therapies to enforce differ-
entiation of TLX1/3+ T-ALL. A similar
approach of ‘‘differentiation therapy’’ has
been extremely effective in the treatment
of acute promyelocytic leukemia with all-
trans retinoic acid (Kogan and Bishop,
1999). Given that their expression is
normally restricted to embryonic develop-
ment, TLX1/3 could prove to be ideal
targets in the treatment of large fraction
T cell leukemias with limited potential for
adverse side effects.REFERENCES
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Two recent papers published in Nature demonstrate the power of systematic high-throughput pharmaco-
logic profiling of very large, diverse, molecularly-characterized human cancer cell line panels to reveal link-
ages between genetic profile and targeted-drug sensitivity. Known oncogene addictions are confirmed while
surprising complexities and biomarker relationships with clinical potential are revealed.The need to identify predictive biomarkers
of tumor response has intensified with
the era of molecularly-targeted therapies
that exploit addictions and vulnerabilities
in tumorswith identifiablemolecular traits,
in contrast to the one-size-fits-all ap-proach that dominated cytotoxic chemo-
therapy (Yap and Workman, 2012). Two
recent Nature articles describe a system-
atic large-scale approach to this challenge
by high-throughput profiling many tar-
geted agents against hundreds of clini-cally-relevant human cancer cells lines
with detailed genetic annotation (Garnett
et al., 2012; Barretina et al., 2012).
There are three important general take-
home messages from these two studies.
(1) The articles provide themost extensivel 21, April 17, 2012 ª2012 Elsevier Inc. 455
